Keywords
Diagnosis
Treatment
Physical therapy
How to Cite
Abstract
Introduction: Chondrosarcoma is a malignant bone cancer arising from cartilage-producing cells, being resistant to chemotherapy and radiotherapy, with surgery as the main treatment. Objective: To provide a review on etiology, diagnosis, treatment and prognosis of chondrosarcoma. Design: Literature review of studies between 2000 and 2023. Data source: PubMed, Scopus, Google Scholar. Study selection: Clinical trials, cohort studies, case-control studies, and systematic reviews. Results: Etiology includes genetic factors and pre-existing bone conditions, with diagnosis based on clinical evaluation, imaging studies (MRI, CT) and biopsy. Primary treatment is surgery, with options ranging from conservative surgery to amputation in severe cases. Conclusions: Early detection and a multidisciplinary approach are crucial to improve treatment outcomes and long-term survival.
References
Gelderblom H, Hogendoorn PC, Dijkstra SD, et al. The clinical approach towards chondrosarcoma. Oncologist. 2008;13(3):320-9. doi:10.1634/theoncologist.2007-0237.
Amstalden van Hove ER, Siemissen DW, Schmidt H, et al. Chondrosarcoma grading by proteomic analysis of formalin-fixed and paraffin-embedded tissue. Mol Oncol. 2017;11(11):1704-1715. doi:10.1002/1878-0261.12132.
Staals EL, Bacchini P, Bertoni F. Dedifferentiated central chondrosarcoma. Cancer. 2006;106(12):2682-91. doi:10.1002/cncr.21941.
Bovée JV. Multiple osteochondromas. Orphanet J Rare Dis. 2008;3:3. doi:10.1186/1750-1172-3-3.
Giuffrida AY, Burgueno JE, Koniaris LG, et al. Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database. J Bone Joint Surg Am. 2009;91(5):1063-72. doi:10.2106/JBJS.H.00680.
Fromm J, Klein A, Baur-Melnyk A, et al. Survival and prognostic factors in conventional central chondrosarcoma. BMC Cancer. 2018;18(1):849. doi:10.1186/s12885-018-4767-
Italiano A, Di Mauro I, Rapp J, et al. Clinical and biological significance of CDKN2A alterations in chondrosarcoma. Clin Cancer Res. 2015;21(14):3331-9. doi:10.1158/1078-0432.CCR-14-2461.
Chow WA. Update on chondrosarcomas: new molecular insights, treatment advances, and clinical challenges. Curr Opin Oncol. 2020;32(4):323-329. doi:10.1097/CCO.0000000000000648.
Heijden L, Dijkstra PD, Campanacci DA, et al. Giant cell tumor with secondary aneurysmal bone cysts: a comparative analysis of three treatment modalities. J Surg Oncol. 2014;109(8):819-23. doi:10.1002/jso.23589.
Nota SP, Braun Y, Schwab JH, et al. The identification of prognostic factors and survival statistics of conventional central chondrosarcoma. Sarcoma. 2015;2015:623746. doi:10.1155/2015/623746.
van Maldegem AM, Gelderblom H, Palmerini E, et al. Outcome of advanced, unresectable conventional central chondrosarcoma patients treated with imatinib mesylate: A phase II trial. Ann Oncol. 2012;23(1):125-30. doi:10.1093/annonc/mdr034.
Xu J, Huo Z, Zhang Z, et al. Emerging therapeutic agents for chondrosarcoma. Sarcoma. 2020;2020:5170135. doi:10.1155/2020/5170135
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Flavia Avelina Cruzado Ulloa, Glenn Alberto Lozano Zanelly